Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on the day's biggest business stories
Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Humira still won't have a U.S. biosimilar until 2023. Photo: JB Reed / Bloomberg via Getty Images
AbbVie said Thursday it reached a deal with biopharmaceutical firm Samsung Bioepis that prevents Samsung from selling its cheaper copy of AbbVie's blockbuster drug Humira in the U.S. until June 30, 2023. This settlement comes roughly six months after AbbVie inked a similar deal with Amgen.
Why it matters: These settlements guarantee AbbVie will have five more years of monopoly pricing in the U.S. for the top-selling drug in the world, even though biosimilar versions of Humira will be available in Europe this October. Humira has garnered huge profits, spurred in part by routine price hikes from AbbVie.